The Peptide Directory

Not approved (research only)Synthetic gastric pentadecapeptideRecoveryGut health

BPC-157

Not FDA-approved. FDA advisers voted 8–6 (1 abstention) on July 23, 2026 to recommend it for the 503A bulks list; FDA has not acted.

Last reviewed by The Peptide Directory Editorial Team

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in a human gastric protein; it has been studied mainly in rodents for tissue repair and is not FDA-approved for any use.

Key takeaways

  1. Almost all evidence is from animal and cell studies; human data are small pilot studies.
  2. FDA scientists reviewed 5 BPC-157 trials and called them short, small and insufficient to establish safety or effectiveness.
  3. An FDA advisory committee nonetheless voted 8–6 in July 2026 to recommend allowing compounding; the vote is non-binding.
  4. Classified as a doping substance by international sports authorities.

Structure

2D chemical structure of BPC-157 (C62H98N16O22), as depicted by PubChem
Structure: PubChem CID 9941957 (C62H98N16O22, 1,419.5 g/mol). 2D depiction from NCBI PubChem, retrieved October 19, 2026.

Amino-acid sequence of BPC-157, 15 residues: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH

Sequence (15 residues, one-letter code): from the PubChem CID 9941957 record; its molecular formula matches the record's C62H98N16O22.

What makes BPC-157 different?

Unlike most peptides discussed here, BPC-157 has no approved drug version anywhere, so every product in circulation is either compounded or sold as a "research chemical".

How does BPC-157 work?

Animal studies suggest effects on blood-vessel growth (angiogenesis), nitric-oxide signaling and growth-factor pathways involved in healing. These mechanisms have not been confirmed in controlled human trials.

What the clinical evidence actually shows

  • Reviews in 2025 (HSS Journal; Current Reviews in Musculoskeletal Medicine) describe a large preclinical literature and very limited human data.
  • Human pilot studies include a 2024 interstitial cystitis pilot and a 2025 intravenous safety pilot (both in Altern Ther Health Med), each with very small numbers.
  • FDA briefing materials for the July 2026 advisory meeting judged the available trials insufficient for the proposed indications.

How much research exists on BPC-157?

PubMed indexes 222 papers mentioning BPC-157 in the title or abstract, 92 of them from the last five years and 0 tagged as clinical trials (search run October 19, 2026; repeat the search).

Most relevant recent papers

Registered clinical studies

ClinicalTrials.gov lists 4 studies with BPC-157 as an intervention (see all). Most recent:

Side effects

No adequate human safety data exist. Reported concerns include unknown long-term effects, theoretical concerns about promoting blood-vessel growth, and contamination or mislabeling risks with unregulated products.

Regulatory & access status

  • Not FDA-approved. FDA restricted compounding with BPC-157 in 2023.
  • July 23, 2026: the Pharmacy Compounding Advisory Committee voted 8–6 with 1 abstention to recommend adding BPC-157 to the 503A bulks list, against FDA staff's recommendation.
  • Legal compounding still requires FDA to accept the recommendation and finish notice-and-comment rulemaking.

Sourcing & safety

Products sold online as "research use only" are not for human use and are not made to drug standards. If you see a vendor's certificate of analysis, check the lab, the lot number and the date (see our COA guide).

Doses in labels and trials

Reference only — copied from published research. Not a recommendation.

SourceWhat it says
Human doseThere is no established or approved human dose. Pilot studies used single protocols in very small groups and do not establish a dose.

What the evidence does not show

  • Effectiveness for any condition in an adequately powered human trial.
  • Long-term safety in humans.
  • That an advisory vote makes compounding legal — it does not.

BPC-157 FAQ

Is BPC-157 FDA-approved?

No. BPC-157 is not approved for any use. An FDA advisory committee voted 8–6 on July 23, 2026 to recommend allowing compounding, but the FDA has not adopted that recommendation.

Is BPC-157 legal to compound now?

Not yet. The FDA must accept the committee's non-binding vote and complete rulemaking before 503A pharmacies can legally compound it.

Is there human evidence for BPC-157?

Only small pilot studies. FDA reviewers called the five available trials too short and too small to establish safety or effectiveness.

Is BPC-157 banned in sport?

Yes — it is classified as a doping substance by international sports authorities.

Related peptides & comparisons

TB-500GHK-CuMOTS-c BPC-157 vs TB-500 Injury & Recovery

References

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS J (2025), PMID 40756949
  2. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, Curr Rev Musculoskelet Med (2025), PMID 40789979
  3. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study, Altern Ther Health Med (2024), PMID 39325560
  4. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study, Altern Ther Health Med (2025), PMID 40131143
  5. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, FDA (2026)
  6. FDA Panel Backs 6 Peptides for Compounding, AJMC (2026)
  7. BPC-157 — PubChem compound summary (CID 9941957), PubChem

BPC-157 calculators

Lab arithmetic only: convert a mass to a volume or syringe units at a known concentration with the units converter, or work out a concentration with the reconstitution calculator.

There is no FDA-approved BPC-157 product. Compounded versions depend on FDA's compounding rules, and "research use only" products are not for human use.

Get BPC-157 via telehealth

Research suppliers that list BPC-157

39 vendors in our directory listed a product matching BPC-157 in their public catalog on October 19, 2026. Listed alphabetically; a listing is not an endorsement. Research use only.

Prices per mg, where we could verify them, are on our price comparison.

BPC-157 dosing protocol

There is no FDA-label or published-trial dosing schedule we can reproduce for BPC-157, so we don't publish one.

Find clinics offering BPC-157

88 verified clinics name BPC-157; browse them by state.

Browse all clinics